References
- Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. Int J Health Care Finance Econ. 2005;5:47–73.
- Warraich HJ, Hernandez AF, Allen LA. How medicine has changed the end of life for patients with cardiovascular disease. J Am Coll Cardiol. 2017;70:1276–89.
- Vaiserman AM, Marotta F. Longevity-promoting pharmaceuticals: is it a time for implementation? Trends Pharmacol Sci. 2016;37:331–33.
- Godman B, Bucsics A, Bonanno PV, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018; 6.
- New products and new indications in 2016: a system that favours imitation over the pursuit of real progress. Rev Prescrire. 2017: 132–136.
- New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Rev Prescrire. 2016:133–137.
- Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8:77–94.
- Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012;2:303–336.
- Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature. 2011;469:83.
- Hawkes N. Drug company Aspen faces probe over hiking generic prices. BMJ Br Med J Online. 2017;57.
- Kober K, Van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet. 2004;364:103–107.
- T Hoen E. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chicago J Int Law. 2002;3:27.
- Ortiz-Prado E, Ponce J, Cornejo-Leon F, et al. Analysis of health and drug access associated with the purchasing power of the ecuadorian population. Global J Health Sci Int. 2017;9:201-210.
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:06–198.
- Kostić M, Djakovic L, Šujić R, et al. Inflammatory bowel diseases (Crohn s Disease and Ulcerative Colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15:85–93.
- Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279.
- Schweitzer SO, Lu ZJ. Pharmaceutical economics and policy: perspectives, promises, and problems. Oxford University Press; 2018.Oxford, UK.
- Kremer M. Pharmaceuticals and the developing world. J Econ Perspect. 2002;16:67–90.
- Kwon H-Y, Kim H, Godman B. Availability and affordability of drugs with a conditional approval by the European medicines agency; comparison of Korea with other countries and the implications. Front Pharmacol. 2018;9:1-9.
- Ortiz-Prado E, Galarza-Maldonado C, Cornejo L, et al. Acceso a medicamentos y mercado farmacéutico en Ecuador. Rev Panam Salud Pública. 2014. Available from: http://www.paho.org
- Novartis access scheme launches in Kenya. PMLive; 2015 [cited 2019 Jul 2]. Available from: http://www.pmlive.com/pharma_news/novartis_access_scheme_launches_in_kenya_846296
- Sandoz a Novartis Division. Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases; 2015 [cited 2019 Jul 4]. Available from: https://www.sandoz.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment
- Gilead to give country of Georgia free hepatitis C treatment. Hep; 2015 [cited 2019 Jul 4]. Available from: https://www.hepmag.com/article/georgia-free-hcv-treatment-27132-377943497
- SMG B, Issa VS, Ayub-Ferreira SM, et al. Reverse auction: a potential strategy for reduction of pharmacological therapy cost. Arq Bras Cardiol. 2015;105:265–275.
- Atun R, LOM DA, Almeida G, et al. Health-system reform and universal health coverage in Latin America. Lancet. 2015;385:1230–1247.
- Lucio R, Villacrés N, Henríquez R. Sistema de salud de Ecuador. Salud Pública México. 2011;53:177–187.
- Cruzado-Sánchez D, Bedriñana-Arones L, Mayta-Salinas E, et al. Precios de medicamentos genéricos en establecimientos públicos y privados de los hospitales de Lima. CIMEL. 2007 [accessed 2019 Apr 10];12(2). Available from: https://www.redalyc.org/html/717/71712204/
- Madden J, Meza E, Ewen M, et al. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey. Rev Panam Salud Publica. [cited 2019 Apr 10];27(4):291–299. Available from: https://www.scielosp.org/article/rpsp/2010.v27n4/291-99/
- Júnior RLM, Godói IP, Reis EA, et al. Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications; 2018.
- Espinosa V, de la Torre D, Acuña C, et al. Los recursos humanos en salud según el nuevo modelo de atención en Ecuador. Rev Panam Salud Pública. 2017;41:e52.
- Ortiz-Prado E. Mercado Farmaceutico Ecuatoriano. 1st ed. Quito, Ecuador: Udla Ediciones; 2018.
- Busch SH, Golberstein E, Meara E. ACA dependent coverage provision reduced high out-of-pocket health care spending for young adults. Health Aff (Millwood). 2014;33:1361–1366.
- Barros AJ, Bertoldi AD. Out-of-pocket health expenditure in a population covered by the family health program in Brazil. Int J Epidemiol. 2008;37:758–765.
- Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240–249.
- Pavic M, Pfeil AM, Szucs TD. Estimating the potential annual welfare impact of innovative drugs in use in Switzerland. Front Public Health. 2014;2. DOI:10.3389/fpubh.2014.00048.
- Crisante M Mercado Farmaceutico y acceso a medicamentos en el Peru; 2013. Available from: http://www1.paho.org/per/images/stories/FtPage/2013/Mercado_farmaceutico-acceso_medicamentos-Peru.pdf. Last accessed March 2019.
- Torres Guerra S, Gutiérrez JP Mercado farmacéutico en México: tamaño, valor y concentración; 2009.[cited 2017 Jul 31]. Available from: http://iris.paho.org/xmlui/handle/123456789/9805
- Schofield I. Generic bashing: effective but illegal traslated from Generic bashing back in vogue?. Rev Prescrire. 2013;(3650):20.
- Shrank WH, Liberman JN, Fischer MA, et al. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45:31–38.
- Tsaprantzi AV, Kostagiolas P, Platis C, et al. The impact of information on doctors’ attitudes toward generic drugs. Int J Health Care Organ Provides Finance. 2016;53:0046958016637791.
- Yang W. How does the pharmaceutical industry influence prescription? A qualitative study of provider payment incentives and drug remunerations in hospitals in Shanghai. Health Econ Policy Law. 2016;11:379–395.
- Mackey TK, Liang BA, York P, et al. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. Am J Trop Med Hyg. 2015;92:59–67.
- Bate R, Mathur A. Corruption and medicine quality in Latin America: A pilot study. BE J Econ Anal Policy. 2017;44:743–754.
- Babar A, Khan B, Godman B, et al. Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future. Generics Biosimilars Initiat J. 2016;5:156–163.
- Fadare JO, Adeoti AO, Desalu OO, et al. The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Rev Pharmacoecon Outcomes Res. 2016;16:639–650.
- Ortiz-Prado E, Fors M, Henriquez-Trujillo AR, et al. Attitudes and perceptions of medical doctors towards the local health system: a questionnaire survey in Ecuador. BMC Health Serv Res. 2019;19:363.
- Kanavos P, Vandoros S. Competition in prescription drug markets: is parallel trade the answer? Manage Decis Econ. 2010;31:325–338.
- Kaplan WA, Ritz LS, Vitello M. Local production of medical technologies and its effect on access in low and middle income countries: a systematic review of the literature. South Med Rev. 2011;4:51.
- Caires de Souza AL, de Assis Acurcio F, Guerra Júnior AA, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12:19–32.
- Yang D. Compulsory licensing: for better or for worse, the done deal lies in the balance. 2012. New Delhi, India.
- Saroha S, Kaushik D, Nanda A. Compulsory licensing of drug products in developing countries. J Generic Med. 2015;12:89–94.
- Bond EW, Saggi K. Compulsory licensing, price controls, and access to patented foreign products. J Dev Econ. 2014;109:217–228.
- Vella S, Wilson D. Access to medicines: lessons from the HIV response. Lancet HIV. 2017;4:e147–e149.
- Harrelson JA TRIPS, pharmaceutical patents, and the HIV/AIDS crisis: finding the proper balance between intellectual property rights and compassion. In: Widener L. Symp. J. HeinOnline; 2001. p. 175.Doha, Qatar.
- Steinbrook R. Thailand and the compulsory licensing of efavirenz. N Engl J Med. 2007;356:544–546.
- Dávila AL. Global pharmaceutical development and access: critical issues of ethics and equity. MEDICC Rev. 2011;13:16–22.
- Chaves GC, Oliveira MA. A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement. Bull World Health Organ. 2007;85:49–56.
- Abrams HB. Copyright’s First Compulsory License. St Clara Comput High Tech LJ. 2009;26:215.
- Reichman JH. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options. J Law Med Ethics. 2009;37:247–263.
- FM’t Hoen E TRIPS, pharmaceutical patents and access to essential medicines: seattle, Doha and beyond; 2002 [cited 2017 Jun 22]. Available from: http://cdrwww.who.int/entity/intellectualproperty/topics/ip/tHoen.pdf
- Izquierdo Aguirre A. burduk Peter M. Licencias obligatorias sobre patentes en la Comunidad Andina: usos de las flexibilidades del ADPIC en Colombia y Ecuador. Foro Rev Derecho Merc. 2013;40:53–83.
- Brown Del Rivero A, Torres CP. La relación comercial Comunidad Andina-Unión Europea y la postura de Ecuador. Latinoam Rev Estud Latinoam. 2012;55:75–99.
- Abbott F. The Doha Declaration on the TRIPS Agreement and public health and the contradictory trend in bilateral and regional free trade agreements; 2011.
- Correa R. Decreto 118; 2009. Available from: http://www.wipo.int/edocs/lexdocs/laws/es/ec/ec035es.pdf. Last accessed March 2019.
- IEPI. Instructivo para la Concesión de Licencias Obligatorias sobre Patentes de Fármacos. Resolución N° 10-04 P-IEPI; 2014 [cited 2014 Jan 21]. Available from: http://www.wipo.int/wipolex/es/details.jsp?id=8062
- Chien CV. Cheap drugs at what price to innovation: does the compulsory licensing of pharmaceuticals hurt innovation? Rochester, NY: Social Science Research Network; 2004 [cited 2014 Jul 28]. Available from: http://papers.ssrn.com/abstract=486723.
- Saez C. Ecuador grants first compulsory licence, For HIV/AIDS drug. Intellect Prop Watch. 2010;22.
- WIPO. Patent landscape report on ritonavir. World Intellect Prop Organ. 2011 [accessed 2019 Jul 2]. Available from: https://www.wipo.int/publications/es/details.jsp?id=230&plang=EN
- MSP. Informe GAM Ecuador. Monitoreo Global de SIDA; 2017. Available from: https://www.unaids.org/sites/default/files/country/documents/ECU_2017_countryreport.pdf. Last accessed June 2019.
- Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Bmj. 2011;342:c7086.
- WIPO. Committee on development and intellectual property (CDIP): thirteenth session. World Intellect Prop Organ. 2014 [cited 2019 Jul 2]. Available from: https://www.wipo.int/meetings/en/details.jsp?meeting_id=32087
- Google Patents. Method of treating tumors in mammals with 2ʹ,2ʹ-difluoronucleosides. US5464826A; 2019 [cited 2019 Jul 2]. Available from: https://patents.google.com/patent/US5464826
- Wang M-H. Recent patent litigation on pharmaceuticals in great China. NTUT J Intell Prop Mgmt. 2013;2:58–68.
- DrugBank. Everolimus; 2019 [cited 2019 Jul 2]. Available from: https://www.drugbank.ca/drugs/DB01590
- Chavez-MacGregor M, Barlow WE, Pusztai L, et al. Abstract OT1-03-11: phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy±one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207. AACR; 2016. (NCT01674140)
- Staton T Afinitor - Novartis. FiercePharma; 2019 [cited 2019 Jul 2]. Available from: https://www.fiercepharma.com/special-report/afinitor-novartis
- DrugBank. Sunitinib; 2019.[cited 2019 Jul 2]. Available from: https://www.drugbank.ca/drugs/DB01268
- Helfand C Sutent - Pfizer. FiercePharma; 2019 [cited 2019 Jul 2]. Available from: https://www.fiercepharma.com/special-report/sutent
- Novartis. Novartis Q4 and FY 2017; 2018. Available from: https://www.novartis.com/sites/www.novartis.com/files/2018-01-interim-financial-report-en.pdf. Last accessed June 2019.
- Vondeling GT, Cao Q, Postma MJ, et al. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16:653–660.
- DrugBank. Sitagliptin; 2019 [cited 2019 Jul 2]. Available from: https://www.drugbank.ca/drugs/DB01261
- Gibney M. Januvia Merck & Co. FiercePharma; 2019 [cited 2019 Jul 2]. Available from: https://www.fiercepharma.com/special-report/16-januvia
- Whitley HP. Sitagliptin (Januvia) for the treatment of patients with type 2 diabetes. Am Fam PHYSICIAN. 2007;76:861–62.
- Brooks P, Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag. 2006;2:45.
- Google Patents. Substituted pyridines as selective cyclooxygenase-2 inhibitors. WO1998003484A1; 2013 [cited 2019 Jul 2]. Available from: https://patents.google.com/patent/WO1998003484A1/en
- Pharmacompass. Etoricoxib | annual Sales Report |. Pharmacompass.com; 2019 [cited 2019 Jul 2]. Available from: https://www.pharmacompass.com/sales-forecast/etoricoxib
- Cruz FO. Production and innovation. Fiocruz. [cited 2019 Jul 4]. Available from: https://portal.fiocruz.br/en/production-and-innovation
- Lexchin J. After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy. 1997;40:69–80.
- Halme M, Linden K, Kääriä K. Patients’ preferences for generic and branded over-the-counter medicines. Patient Patient-Centered Outcomes Res. 2009;2:243–55.
- Medicamentarius. Comparación de precios a público entre Chile y Otros países (Abril 2017). Chile: Colegio de Químicos Farmaceúticos y Bioquímicos de Chile; 2017. Available from: http://web.camara.cl/verDoc.aspx?prmID=137626&prmTipo=documento_comision
- Ministerio de Salud de Perú. Observatorio Peruano de Productos Farmacéuticos. Sist Nac Inf Precios. 2019 [accessed 2019 Jul 3]. Available from: http://observatorio.digemid.minsa.gob.pe/?over=1
- CENSIDA. Precios medicamentos antirretrovirales 2016. México: 2016. Available from: http://www.censida.salud.gob.mx/descargas/arv.pdf. Last accessed May 20 2019.
- Secretaría de Economía Mexico. Precios de medicamentos de patente de SE − 2015; 2015 [cited 2019 Jul 3]. Available from: https://datos.gob.mx/busca/dataset/precios-de-medicamentos-de-patente-de-se/resource/f7c8ae08-fe46-430d-bbef-ea44bddf3a2b
- Gustafsson LL, Wettermark B, Godman B, et al. The ‘wise list’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224–233.
- Björkhem-Bergman L, Andersén-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol. 2013;69:73–78.
- Eriksen J, Gustafsson LL, Ateva K, et al. High adherence to the ‘Wise List’treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017;7:e014345.